氘可来昔替尼(Deucravacitinib) - 药物靶点：TYK2_在研适应症：红皮病性银屑病，寻常性银屑病，脓疱型银屑病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Deucravacitinib (USAN)、德卡伐替尼、BMS-986165

+ [5]

靶点

TYK2

作用方式

抑制剂

作用机制

TYK2抑制剂(酪氨酸蛋白激酶TYK2抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病感染+ [4]

在研适应症

红皮病性银屑病寻常性银屑病脓疱型银屑病+ [10]

非在研适应症

斑秃克罗恩病泛发性脓疱型银屑病+ [9]

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIGBristol-Myers Squibb Australia Pty Ltd.

+ [2]

非在研机构

Dartmouth-Hitchcock Medical Center

百时美施贵宝（中国）投资有限公司

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-09-09),

斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C20H22N8O3

InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N

CAS号1609392-27-9

关联

92

项与氘可来昔替尼相关的临床试验

NCT06979453

/ Recruiting临床3期

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

开始日期2025-12-03

申办/合作机构

Bristol Myers Squibb Co.

NCT07012057

/ Withdrawn临床2期IIT

A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis

Background:
Dermatomyositis (DM) and juvenile dermatomyositis (JDM) are diseases that weaken the immune system. DM and JDM can affect the muscles, skin, joints, and lungs and cause skin rashes and muscle inflammation. Symptoms include weakness, pain, fatigue, and rash. Not everyone responds to current treatments. The FDA has approved a drug called deucravacitinib to treat people with plaque psoriasis. Researchers want to find out if this drug can help people with DM or JDM, too.
Objective:
To test deucravacitinib in people with DM or JDM.
Eligibility:
People aged 18 years and older with DM or JDM.
Design:
Participants will have 9 clinic visits over 28 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests. They will have a test of their heart function. They will complete a short questionnaire about their daily life, pain level, and ability to walk, eat, and do other activities.
Deucravacitinib is a pill taken by mouth twice per day at home. Participants will come to the clinic once every 4 weeks for 24 weeks while they are taking the drug. They will have a final visit 4 weeks after their last dose of the study drug. Blood and urine tests will be repeated during these visits. Each visit may take up to 6 hours.
If the drug is helping them, participants may extend their treatment beyond the first 24 weeks. Then they will visit the clinic every 3 months.

开始日期2025-11-21

申办/合作机构-

NCT07116967

/ Recruiting临床3期

A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

开始日期2025-09-22

申办/合作机构

Bristol Myers Squibb Co.

100 项与氘可来昔替尼相关的临床结果

登录后查看更多信息

100 项与氘可来昔替尼相关的转化医学

登录后查看更多信息

100 项与氘可来昔替尼相关的专利（医药）

登录后查看更多信息

298

项与氘可来昔替尼相关的文献（医药）

2026-01-01·CORNEA

Conversion of Conjunctival Nevus to Melanoma in a Patient Taking the TYK2 Inhibitor Deucravacitinib

Article

作者: Whitcomb, Nicholas ; Lee, Hyunjoo J.

Purpose::

To describe a case of a patient with a preexisting conjunctival nevus giving rise to conjunctival melanoma as a potential adverse effect of the new selective Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitor deucravacitinib.

Methods::

Single case report.

Results::

A 50-year-old woman with a medical history of psoriasis, for which she was 6 months into treatment with deucravacitinib, presented with 3 months of progressive enlargement and darkening of a brown-pigmented lesion in the left eye. This lesion evolved in the place of a pigmented nodule in the left eye that had been present and unchanging for at least several years prior. Urgent surgical excision, cryotherapy, and ocular surface reconstruction were performed without complication. Biopsy of the lesion confirmed the presence of a conjunctival melanoma, invasive to a depth of 0.7 mm, arising from a precursor conjunctival nevus. The patient was subsequently referred to an oncologist, who recommended discontinuing deucravacitinib.

Conclusions::

Deucravacitinib-mediated inhibition of tyrosine kinase 2 (TYK-2) disrupts signaling of cytokines interferon alpha (IFN-α), interleukin (IL)-12 and IL-23, providing a theoretical mechanism for increased risk of malignancy while taking the drug. In this case, the temporal relation between starting deucravacitinib treatment and the rapid growth of a conjunctival melanoma arising from a nevus is concerning for a protumor effect of this immunomodulatory drug. Patients with ocular lesions at risk of malignant transformation should perhaps be closely monitored while on deucravacitinib therapy until more is known regarding the degree of risk of malignant transformation because of immunomodulation from TYK2 inhibition.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan

Article

作者: van de Wetering, Gijs ; Tada, Yayoi ; Roberts, David ; Hikichi, Yusuke ; Kim, Hyunchung ; Smith, Martina

OBJECTIVE:

This study aimed to evaluate the cost-effectiveness of deucravacitinib vs. apremilast as a treatment for moderate-to-severe psoriasis patients from a Japan healthcare system perspective.

METHODS:

A Markov sequence model was developed, consisting of an induction phase, maintenance phase, best supportive care and death. Clinical inputs were predominantly derived from the POETYK-PSO-1 and -2 trials (NCT03624127 and NCT03611751), and cost and resource use inputs were derived from several Japanese sources, including Ministry of Health and Welfare (MHLW) data and the outputs of a Delphi survey with Japanese clinical experts. Health-related quality of life inputs were based on the change in utility associated with different levels of Psoriasis Area and Severity Index (PASI) response. Deterministic and probabilistic sensitivity analyses were conducted to account for uncertainty around the base case and several scenario analyses were performed to explore structural uncertainty related to assumptions and methodological choices.

RESULTS:

In the base case, treatment with deucravacitinib results in a discounted QALY gain of 0.30 and discounted incremental costs of ¥459,771 compared to apremilast, resulting in an ICUR of ¥1,546,713 per QALY which is below the Japanese willingness to pay threshold of ¥5,000,000 per QALY. Deterministic and probabilistic sensitivity analyses support the results of the base case. The latter shows that deucravacitinib has a 97.8% probability of being cost-effective compared to apremilast at the ¥5,000,000 per QALY threshold. The outcomes of all scenarios confirmed the cost-effectiveness of deucravacitinib compared to apremilast, with deucravacitinib being dominant in one scenario.

CONCLUSIONS:

Deucravacitinib is cost-effective compared to apremilast in patients with moderate-to-severe plaque psoriasis in Japan, primarily driven by improvements in health-related quality of life associated with a more favorable PASI response. This conclusion is supported by extensive sensitivity and scenario analyses.

2025-12-31·ANNALS OF MEDICINE

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis

Review

作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing

BACKGROUND AND OBJECTIVE:

Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.

PATIENTS AND METHODS:

Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.

RESULTS:

A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.

CONCLUSIONS:

Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.

559

项与氘可来昔替尼相关的新闻（医药）

2025-12-05

·北京卫人医院官方挂号

特殊部位银屑病：局部治疗困境与治疗策略更新

头皮、指甲、掌跖、生殖器等特殊部位的银屑病，因局部解剖结构、皮肤屏障及功能需求的特殊性，使得常规的外用药治疗常因渗透不足、使用不便或耐受性差而难以奏效，给患者带来显著的生理与心理负担。美国耶鲁大学医学院的Bruce Strober教授结合最新临床证据，对特殊部位银屑病的治疗策略给出了系统建议。 1. 头皮银屑病治疗挑战：毛发阻碍药物附着与渗透，影响疗效。核心治疗证据：生物制剂疗效突出：在头皮清除率方面，IL-17抑制剂（如依奇珠单抗、司库奇尤单抗）表现最优。研究显示，治疗第16周，近60%的患者可实现头皮皮损完全清除，其疗效优于IL-23抑制剂。小分子药物选择：TYK2抑制剂（氘可来昔替尼）在头皮清除效果上优于PDE4抑制剂（阿普米司特）。治疗阶梯建议：IL-17抑制剂 > IL-23抑制剂 > JAK抑制剂。需注意：目前，仅有古塞奇尤单抗（IL-23抑制剂）、司库奇尤单抗（IL-17抑制剂）和阿普米司特（PDE4抑制剂）在其美国FDA药品说明书中明确包含了治疗头皮银屑病的有效性数据。 2. 掌跖银屑病/掌跖脓疱病治疗挑战：角质层厚，药物渗透难；日常摩擦、接触多，易受刺激。核心治疗证据：针对难治性的掌跖脓疱病（PPP），临床研究表明，阿普米司特、布罗利尤单抗（IL-17受体抑制剂）和古塞奇尤单抗显示出优于安慰剂的疗效。治疗阶梯建议：JAK抑制剂 > IL-23或IL-17抑制剂 > 甲氨蝶呤 > 氘可来昔替尼 > 生物制剂联合口服系统性药物。 3. 反向型银屑病（间擦部位/生殖器）治疗挑战：皮肤薄嫩敏感，对激素等外用药物耐受性差，易发生不良反应。核心治疗证据：系统治疗：推荐使用IL-23抑制剂、IL-17抑制剂、阿普米司特、氘可来昔替尼。局部治疗：一线选择：推荐非激素类外用药物，如维生素D衍生物、钙调神经磷酸酶抑制剂（如他克莫司）、Roflumilast乳膏（PDE4抑制剂）、Tapinarof乳膏（芳香烃受体调节剂）。慎用药物：强效糖皮质激素需非常谨慎地短期使用，以避免皮肤萎缩等副作用。联合治疗：可考虑联合局部窄谱中波紫外线（NB-UVB）治疗。 4. 甲银屑病治疗挑战：甲板坚硬，药物难以穿透至甲母质及甲床的病变部位。核心治疗证据：局部治疗：可选择维生素D衍生物、钙调神经磷酸酶抑制剂、维A酸、水杨酸外用，或联合使用。对于顽固性甲周病变，可考虑糖皮质激素局部注射。系统治疗：传统药物：甲氨蝶呤、阿维A。新型药物：生物制剂、JAK抑制剂、TYK2抑制剂。疗效数据：在生物制剂中，利生奇珠单抗（IL-23抑制剂）在长期维持治疗中显示出更优的稳定性。口服药方面，氘可来昔替尼和乌帕替尼对甲银屑病的清除率约在50%左右。 5. 泛发性脓疱型银屑病治疗挑战：急性发作可危及生命，传统治疗疗效有限，需快速控制。核心治疗证据：靶向治疗突破：佩索利单抗是目前FDA唯一批准的、针对GPP的IL-36受体单克隆抗体，能快速有效控制病情并减少复发。管理要点：约70%的GPP患者合并其他系统性疾病（如感染、代谢综合征等），治疗时必须关注全身状况，进行长期综合管理。总结特殊部位银屑病的治疗需“因地制宜”，结合皮损部位的特点选择穿透性佳、安全性高的药物。治疗策略已从依赖局部治疗，转向更积极地应用靶向生物制剂（如IL-17、IL-23抑制剂）和新型小分子药物（如JAK/TYK2抑制剂），这些药物在临床研究中显示出对传统“治疗困境”部位的卓越疗效。临床决策需基于皮损部位、严重程度、患者共病及治疗偏好综合制定。名医档案主任课堂（我院提供专业的问诊渠道，点击文章下方“阅读原文” 联系我院咨询哦）

临床结果

2025-12-05

·医研新招募

【中重度斑块银屑病】口服TYK2抑制剂CS32582胶囊患者招募中！

银屑病是一种免疫介导的慢性、复发性、炎症性皮肤病，典型皮损临床表现为鳞屑性红斑或斑块于皮肤局限或广泛分布。银屑病可在任何年龄段发病，病程长，易反复，给患者的社会交往、生活质量、就医负担及身心健康等带来极大影响。目前银屑病常见的治疗手段包括局部治疗、光疗、传统系统治疗、中药治疗、生物制剂治疗等。近年来，生物制剂已经成为银屑病的主要系统用药，在治疗中重度、难治性及特殊类型银屑病方面发挥积极而有效的作用。而越来越多的证据表明，IL-23/Th17轴在银屑病发病中可能处于关键环节，针对特异性靶点的生物制剂在银屑病患者身上也显现出了良好的安全性和有效性。 CS32582是微芯生物自主研发的一款酪氨酸激酶2（TYK2）高选择性小分子变构抑制剂，通过特异性结合TYK2的调节性假激酶JH2结构域，实现对TYK2选择性抑制，且在治疗剂量下不会抑制同家族激酶JAK1、JAK2和JAK3，发挥治疗作用的同时带来良好的安全性。CS32582对TYK2的抑制能有效阻断白介素（IL）-23、IL-12和Ⅰ型干扰素（IFN）等细胞因子介导的的下游信号通路，从而发挥对银屑病等自身免疫性疾病的治疗作用。临床前研究显示其在小鼠银屑病模型中起到了显著的治疗效果。【试验标题】在中重度斑块银屑病成人患者中评价CS32582胶囊有效性和安全性的多中心、随机、双盲、安慰剂对照的Ib/II期临床试验【适应症】中重度斑块银屑病【研究用药】实验组：CS32582胶囊对照组：安慰剂药物介绍：CS32582是微芯生物自主研发的一款酪氨酸激酶2（TYK2）高选择性小分子变构抑制剂，通过特异性结合TYK2的调节性假激酶JH2结构域，实现对TYK2选择性抑制，且在治疗剂量下不会抑制同家族激酶JAK1、JAK2和JAK3，发挥治疗作用的同时带来良好的安全性。CS32582对TYK2的抑制能有效阻断白介素（IL）-23、IL-12和Ⅰ型干扰素（IFN）等细胞因子介导的的下游信号通路，从而发挥对银屑病等自身免疫性疾病的治疗作用。临床前研究显示其在小鼠银屑病模型中起到了显著的治疗效果。【入选重点】 1.年龄18~70周岁，性别不限 2.诊断为斑块银屑病，且病程≥6个月 3.近期斑块银屑病处于稳定期 4.银屑病受累体面积BSA大于等于10% 【排除标准】 1.存在非斑块状银屑病（红皮病型、脓疱型、点滴状银屑病和药物性银屑病等） 2.存在其他研究者认为会干扰研究评估的皮肤疾病 3.存在免疫相关疾病（如炎症性肠病）需要全身性治疗，非甾体类抗炎药除外 4.使用过其他TYK2抑制剂（如氘可来昔替尼） 5.随机前6个月内，使用过以下治疗药物：靶向IL-12/-23、IL-17或IL-23抗体，如乌司奴单抗、司库奇尤单抗、替瑞奇珠单抗、依奇珠单抗或古塞奇尤单抗等；利妥昔单抗或其他细胞耗竭剂；来氟米特 6.随机前2个月内使用过肿瘤坏死因子（TNF）抑制剂，如依那西普、阿达木单抗、英夫利昔单抗、培塞利珠单抗等 7. 随机前3个月或5个半衰期（以较长者为准）接受任何银屑病治疗生物制剂【患者权益】 1.研究期间相关检查免费 2.研究药物免费使用 3.专家定期随访及相关检查 4.权威的医疗专家对疾病的指导 5.一定的交通补助【研究中心】 1.北京大学人民医院 2.河北医科大学第一医院 3.山西医科大学第一医院 4.西安交通大学第二附属医院 5.首都医科大学附属北京友谊医院 6.温州医科大学附属第一医院 7.浙江大学医学院附属第四医院 8.承德医学院附属医院 9.山东省皮肤病医院 10.十堰市人民医院 11.杭州市第一人民医院【报名资料】 1.确诊≥6个月的银屑病病例 2.近一周皮损照片 3.近期合并用药参与临床试验，获取国际前沿新药新疗法使用机会！更有一线专家团队为你的治疗保驾护航！【医研新招募】目前有多个慢病的临床试验正在招募患者！扫码添加下图微信报名咨询注：此项目为临床试验项目，具体开展时间、补助等详情，请以研究中心通知和知情同意书为准，更多项目请关注“医研新招募“公众号。

临床结果临床2期

2025-12-04

·皮肤科Dr徐斌

告别针头？口服药也能实现“皮肤清零”，银屑病治疗迎来新突破！

皮肤科 Dr 徐斌医者丨跑者丨读者一起做个有趣的人 “Icotrokinra正试图弥合传统口服药与注射生物制剂之间的鸿沟，用一片药丸的便捷，承载起生物制剂级别的高效希望。” “医生，我实在不想再打针了，有没有效果好一点的口服药？”“每次想到要打针，心里就发怵，要是能吃药就好了……” 在皮肤科门诊，我们经常听到中重度斑块状银屑病患者这样的心声。今天，就为大家带来一个好消息：一项最新的国际临床研究，发现了一种名为Icotrokinra的新型口服药，其效果可媲美注射型生物制剂，有望为银屑病患者提供高效、便捷的新选择。一、治疗银屑病，为何大家渴望口服药？目前，中重度银屑病的“王牌”治疗是生物制剂（如司库奇尤单抗、乌司奴单抗等）。它们效果显著，但需要注射，存在以下不便：用药不便：需定期前往医院或自行注射，对怕针、晕针者不友好。成本较高：生产和储存（部分需冷链）成本高。可及性差：部分地区的患者难以获得。而现有的口服药（如阿普斯特、氘可来昔替尼），虽然方便，但效果通常不如生物制剂。有没有一种药，能兼顾“口服的便捷”和“生物制剂的高效”呢？新药Icotrokinra的出现，正是为了填补这一空白。二、什么是Icotrokinra？它如何精准打击银屑病？ Icotrokinra（研发代号JNJ-77242113）是一种靶向口服肽。您可以把它理解为一位拥有精准导航系统的“口服特工”。作用靶点：它精准地锁定在免疫细胞表面的 IL-23受体上。作用原理：IL-23是驱动银屑病炎症的“关键开关”之一。Icotrokinra通过阻断IL-23与受体结合，从源头上切断下游的炎症信号，从而达到治疗目的。独特之处：它与目前主流的注射型生物制剂（靶向IL-23的p19亚基）作用位点不同，但最终目标一致——抑制IL-23通路。这种精巧的设计使其能够以药片的形式被服用，并在体内发挥强大作用。三、效果如何？临床数据告诉你答案两项大型国际三期临床试验（ICONIC-ADVANCE 1 & 2 和 ICONIC-LEAD）结果均发表在顶级医学期刊上，结果令人振奋。主要疗效数据（治疗16周后）疗效指标 (治疗16周) Icotrokinra组安慰剂组效果解读皮肤几乎完全清洁 (IGA 0/1)65% - 70%8% - 11% 约2/3的患者达到皮损几乎看不见的状态PASI 90（改善90%以上）50% - 57%1% - 4% 超过一半的患者皮损面积和严重度改善超90%皮肤完全清洁 (PASI 100)27% - 32%<1% 近三分之一患者实现“皮肤清零”头皮银屑病显著改善72%15% 对难治的头皮部位效果同样出色起效速度快：部分患者在用药后4周就开始看到明显改善。效果持续增强：随着用药时间延长至24周，实现“皮肤清零”（PASI 100）的患者比例从27%上升至40%。对比现有口服药：在研究设计中，Icotrokinra的疗效显著优于另一种先进口服药氘可来昔替尼，实现皮肤完全清洁的患者比例是后者的约2倍。四、安全性怎么样？在16周的短期治疗中，Icotrokinra组的不良事件发生率（49%）与安慰剂组（49%）相当。最常见的不良反应是鼻咽炎和上呼吸道感染，发生率与安慰剂组无差异。胃肠道反应：发生率较低（约6%），与安慰剂组相似。长期安全性：目前最长随访至24周，数据显示安全性良好，暴露校正后的不良事件发生率保持稳定。但更长期的（如数年）安全性数据仍在收集中。五、客观看待：新药的局限性与未来尽管前景光明，但我们仍需客观看待：长期数据尚不完善：52周及更长期的疗效与安全性数据仍在研究中。停药后能否维持？关于停药后症状是否会复发，以及如何维持疗效，需要进一步的“随机撤退”研究来解答。真实世界表现：临床试验条件严格，在实际临床应用中的效果可能略有差异。便利性的另一面：每日口服需要患者有良好的依从性，而数月注射一次的生物制剂可能让患者在治疗间歇期“忘记”疾病。三点核心信息 (Take Home Message)高效便捷新选择：Icotrokinra作为一种口服药，在清除皮损方面展现了与注射型生物制剂相媲美的高效性，为患者提供了“鱼与熊掌兼得”的新选项。作用机制精准：它通过精准阻断IL-23受体这一关键炎症通路起效，从源头抑制银屑病的发展。短期安全性良好：现有数据显示其短期安全性与安慰剂相似，常见不良反应多为轻微感染，但更长远的疗效与安全性仍需时间验证。参考文献Bissonnette, R., Soung, J., Hebert, A. A., et al. (2025). Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. New England Journal of Medicine, 393(18), 1784-1795. Puig, L. (2025). Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy. The Lancet, 406(10420), 1257-1259. Stein Gold, L., Armstrong, A. W., Bissonnette, R., et al. (2025). Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. The Lancet, 406(10420), 1363-1374. 本文内容仅供参考，不能替代专业医疗建议。往期精彩：打疫苗就能预防“缠腰龙”？皮肤科医生教你最有效的一招！跑个马拉松，大脑“掉层皮”？顶级期刊《自然·代谢》科学家发现髓鞘可逆减少，揭示运动大脑的惊人智慧！为什么肤色有深浅？科学发现：竟与两种维生素的“皮肤博弈”有关！标个星，不走散 --- E N D --- 徐斌，常州一院皮肤科副主任医师专家门诊时间

100 项与氘可来昔替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11817	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
红皮病性银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
寻常性银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
脓疱型银屑病	日本	Bristol-Myers Squibb KK	2022-09-26
斑块状银屑病	美国	Bristol Myers Squibb Co.	2022-09-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	申请上市	美国	Bristol Myers Squibb Co.	2025-07-21
幼年特发性关节炎	临床3期	美国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	中国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	巴西	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	保加利亚	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	捷克	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	德国	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	意大利	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	罗马尼亚	Bristol Myers Squibb Co.	2025-03-13
幼年特发性关节炎	临床3期	西班牙	Bristol Myers Squibb Co.	2025-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06476834 (CTgov)	临床4期	-	8	Deucravacitinib	顧艱鑰醖餘積壓選鏇願(選鏇蓋壓積壓鏇製糧夢) = 夢蓋網築艱壓齋淵積壓蓋夢夢願積膚遞鏇鏇網 (襯製鑰鹹鹽衊齋築鬱廠, 59.5) 更多	-	2025-12-03
NCT04857034 (PAISLEY DLE/SCLE, ACR2025)	临床2期	皮肤红斑狼疮	32	Deucravacitinib 3 mg BID	遞鏇構夢選觸夢鹹鑰鏇(齋遞夢範壓鹽蓋鏇艱廠) = 鹽鹹窪觸網淵網襯鏇鏇選憲簾鬱鹹獵選醖齋鬱 (簾廠齋壓廠襯鏇鹽廠憲 ) 更多	积极	2025-10-24
NCT04908202 (POETYK PsA-1, ACR2025)	临床3期	银屑病关节炎	670	Deucravacitinib 6 mg QD	蓋鬱衊鹹醖鹽艱醖餘淵(範選壓遞網築壓鬱窪艱) = 鬱積觸積襯願廠壓醖鹹網簾憲壓製積齋構築繭 (夢築夢鏇衊糧蓋襯鬱衊 )	积极	2025-10-24
				Placebo	範獵艱夢鑰鏇積夢餘網(積壓鬱顧醖築遞觸鹹積) = 醖簾齋鹽繭築蓋鑰觸餘蓋網艱襯醖積蓋襯廠簾 (鬱淵簾構膚艱襯淵鹽齋 ) 更多
NCT04908202 (POETYK PsA-1, ACR2025)	临床3期	银屑病关节炎	1,294	Deucravacitinib 6 mg	餘築鬱艱餘鑰範選構鹽(衊鏇鬱壓鬱簾獵餘顧構) = 遞範鬱獵餘製夢膚襯選蓋鏇衊繭憲簾夢淵鏇餘 (襯獵壓壓齋糧窪鹽膚製 ) 更多	积极	2025-10-24
				Placebo	餘築鬱艱餘鑰範選構鹽(衊鏇鬱壓鬱簾獵餘顧構) = 襯衊遞衊衊鏇廠衊艱選蓋鏇衊繭憲簾夢淵鏇餘 (襯獵壓壓齋糧窪鹽膚製 ) 更多
NCT03252587 (PAISLEY SLE, ACR2025)	临床2期	系统性红斑狼疮	363	Deucravacitinib 3 mg BID	窪積築網蓋艱選顧選蓋(醖餘鹽餘鑰獵願鹽醖獵) = occurred in 13.4%, 11.4%, and 17.3% of patients who received deucravacitinib 3 mg BID, 6 mg BID, and 12 mg QD, respectively. 艱窪艱餘衊膚鬱夢淵糧 (膚憲鏇齋衊遞鑰艱鬱醖 ) 更多	积极	2025-10-24
				Deucravacitinib 6 mg BID
NCT04857034 (PAISLEY CLE, ACR2025)	临床2期	皮肤红斑狼疮 IFN-5 \| IFN-γ \| inflammation	78	Deucravacitinib 3 mg twice daily	構襯鬱憲窪觸鹽淵蓋選(衊網艱積衊齋簾鹽網築) = 願餘壓窪壓鏇壓鑰鏇憲遞構獵製艱艱糧窪築醖 (選積鏇醖繭蓋構醖壓獵 )	积极	2025-10-24
				Deucravacitinib 6 mg twice daily	構襯鬱憲窪觸鹽淵蓋選(衊網艱積衊齋簾鹽網築) = 壓衊廠夢蓋衊繭選鏇遞遞構獵製艱艱糧窪築醖 (選積鏇醖繭蓋構醖壓獵 )
NCT04908202 (POEYTK PsA-1 \| POETYK PsA-1, CTgov)	临床3期	银屑病关节炎	670	Deucravacitinib (Placebo-Controlled Period - Deucravacitinib 6 mg QD)	鑰鬱壓糧蓋蓋廠齋糧構 = 遞製糧齋積範顧鏇膚廠襯簾鏇襯襯壓選壓築衊 (蓋壓膚鏇艱糧網醖糧鏇, 鏇廠願醖遞製蓋網積憲 ~ 網壓襯襯衊鹽艱壓築鏇) 更多	-	2025-10-24
				placebo (Placebo-Controlled Period - Placebo)	鑰鬱壓糧蓋蓋廠齋糧構 = 廠獵顧廠衊衊網衊醖觸襯簾鏇襯襯壓選壓築衊 (蓋壓膚鏇艱糧網醖糧鏇, 觸艱積積鏇顧獵鹹觸鏇 ~ 窪繭窪鑰淵獵鑰範夢願) 更多
NCT04908202 \| NCT04908189 (POETYK PsA-2, ACR2025 \| Company_Website) 人工标引	临床3期	银屑病关节炎	670	Placebo (through wk16)	齋顧鏇構獵襯襯醖積蓋(積鏇醖遞艱壓艱鹹鬱製) = 餘築夢衊範構遞繭遞鑰鹽淵憲築襯選膚構觸齋 (廠觸顧顧齋鬱憲築夢網 ) 达到更多	积极	2025-10-13
				Deucravacitinib 6 mg QD (fr wk16 to wk52 (switched from Placebo at wk16))	齋顧鏇構獵襯襯醖積蓋(廠憲壓鹹顧衊膚糧膚願) = 積獵襯蓋夢衊遞獵獵齋獵襯壓齋蓋艱鹹簾廠窪 (窪顧觸鹽餘鬱願選襯繭 ) 更多
NCT03252587 \| NCT03920267 (PAISLEY LTE, ACR2025) 人工标引	临床2期	系统性红斑狼疮	363	Placebo (to week 48)	淵憲鬱餘廠憲範鬱襯鹽(蓋鹹糧網夢鹽衊齋網獵) = 繭衊艱衊積鑰製窪淵糧選鏇範選餘鬱夢餘鬱鬱 (壓範鏇網鏇簾衊鏇顧願 ) 更多	积极	2025-10-13
				Deucravacitinib (3 mg BID, through W226)	淵憲鬱餘廠憲範鬱襯鹽(蓋鹹糧網夢鹽衊齋網獵) = 夢觸壓遞願鏇憲夢廠鹹選鏇範選餘鬱夢餘鬱鬱 (壓範鏇網鏇簾衊鏇顧願 ) 更多
NCT05701995 (ARTISTYK, CTgov)	临床4期	斑块状银屑病	180	BMS-986165 (BMS-986165 6mg QD)	積製廠觸窪繭範觸壓鑰 = 獵糧範鏇齋遞積獵糧淵願鬱壓壓簾網鹽選糧齋 (願壓簾遞範壓醖鑰網糧, 範觸艱築醖糧夢壓鬱遞 ~ 襯製鹽構觸積憲繭鹽齋) 更多	-	2025-09-10
				placebo (Placebo)	積製廠觸窪繭範觸壓鑰 = 憲壓選範製積餘鹽鹽鑰願鬱壓壓簾網鹽選糧齋 (願壓簾遞範壓醖鑰網糧, 築選襯醖築鹹願鹹窪鹹 ~ 觸壓鏇築網衊齋衊糧選) 更多